FocalTherics (EDA) AI Stock Analysis
FocalTherics
(Frankfurt:EDA)
No summary available
FocalTherics (EDA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 156.67M
- Dividend Yield
- ―
- Average Volume (3M)
- 235
- Price to Earnings (P/E)
- -4.0
- Beta (1Y)
- 0.92
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Germany
- Employees
- 289
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
FocalTherics Business Overview & Revenue Model
Company Description
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activitie...
FocalTherics Earnings Call Summary
The call conveyed clear commercial momentum: double-digit revenue growth (39% YoY), record capital system sales, strong procedure volume growth (47% YoY), margin improvement to 55.6%, meaningful regulatory/reimbursement progress, and a near-term $40M equity raise to fund commercial expansion and R&D. Offsetting these positives are rising operating expenses, a sizable noncash warrant charge ($6.3M) that pushed shareholder equity negative ($-3.2M), reliance on the pending equity raise to strengthen the balance sheet, and a 34% decline in discontinued operations revenue. On balance, the business shows accelerating revenue, improving margins and strategic progress that outweigh the financial and accounting headwinds, with the upcoming equity close expected to materially improve capitalization.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated full‑year 2026 continuing‑operations (core HIFU) revenue guidance of $50.0–$54.0 million; Q2 HIFU revenue was $13.2M (up 39% YoY) driven by 13 capital system sales (up 44%) and a worldwide installed base of 184 systems (96 U.S., 88 international), with U.S. procedures up 47% YoY and gross margin rising to 55.6% (from 51.1%); quarter‑end cash was $21.5M (with a $40M underwritten equity offering expected to close Aug 14), shareholder equity was negative $3.2M, Tranche B draws of ~$14M were outstanding under the EIB facility, operating expenses were $15.4M, tariff impact was ~$0.5M, discontinued operations generated $5.6M revenue (‑34%) with 36.4% gross margin and $4.5M inventory, and management noted a proposed ~12% CMS facility payment increase for 2027 and long‑term gross margin aspirations around 60% as it executes its commercial and indication‑expansion strategy.
FocalTherics Risk Analysis
FocalTherics disclosed 43 risk factors in its most recent earnings report. FocalTherics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskFocalTherics Peers Comparison
Overall Rating
APYX45Neutral
XTNT45Neutral
NSPR41Neutral
ICCM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| APYX | 45Neutral | $109.52M | -12.58 | -78.70% | ― | 25.59% | 55.35% |
| XTNT | 45Neutral | $39.31M | -3.40 | -23.45% | ― | -14.27% | -132.84% |
| NSPR | 41Neutral | $20.92M | -0.91 | -79.21% | ― | 53.42% | 22.08% |
| ICCM | 37Underperform | $2.98M | -0.13 | -174.26% | ― | 41.62% | 20.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:EDA | Focaltherics | 3.70 | 1.98 | 115.12% | |
| APYX | Apyx Medical | 2.60 | -0.60 | -18.75% | |
| NSPR | InspireMD Inc | 0.45 | -1.84 | -80.35% | |
| XTNT | Xtant Medical Holdings Inc | 0.28 | -0.53 | -65.47% | |
| ICCM | Icecure Medical Ltd. | 0.87 | -20.96 | -96.01% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.